Clinical Trials Logo

Sorafenib clinical trials

View clinical trials related to Sorafenib.

Filter by:
  • None
  • Page 1

NCT ID: NCT04709380 Recruiting - Radiotherapy Clinical Trials

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

To explore the efficacy of radiotherapy plus toripalimab Versus standard treatment of sorafenib in advanced hepatocellular carcinoma with Portal Vein/Hepatic vein Tumor Thrombosis.

NCT ID: NCT04518852 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Start date: September 14, 2020
Phase: Phase 2
Study type: Interventional

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%. Despite a significant improvement in treatment strategy, the overall survival of HCC remains low due to high recurrence, progressive liver dysfunction and the high fatality of the disease. Surgical resection has been applied in a number of patients; however, surgery has been associated with a high incidence of recurrence (approximately 70% within 5 years). TACE is generally applied on intermediate-stage HCC. However, TACE is not satisfied with improving overall survival. Therefore, there is an urgent need for effective treatment for these patients. At present, the overall objective response rate (ORR) of single or sequential therapy is not satisfied, and the over survival (OS) improvement is not ideal. Therefore, combined therapy maybe the good choice for patients with advanced HCC. This study focuses on the in-operable, BCLC-B/C HCC patients. Through the combination of local therapy (TACE), anti-angiogenic therapy (Sorafenib), and immunotherapy (PD-1 monoclonal antibody), it is expected to change the tumor microenvironment, restore the immune response, strengthen the anti-tumor effect of various treatments, and improve the therapeutic efficacy in patients with BCLC-B/C HCC.

NCT ID: NCT04103398 Completed - Clinical trials for Hepatocellular Carcinoma

TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

TREAT
Start date: October 2, 2019
Phase: Phase 3
Study type: Interventional

The study is a multicenter phase III randomized trial. The purpose is to investigate both the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib versus TACE alone for recurrent intermediate hepatocellular carcinoma patients.

NCT ID: NCT03958669 Terminated - Clinical trials for Hepatocellular Carcinoma

Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC

e:Med-HCC-2
Start date: November 1, 2019
Phase:
Study type: Observational

This study is a prospective evaluation of a multiscale prediction model for the treatment with tyrosine kinase inhibitors (TKI) in HCC. Patients with HCC that qualify for systemic treatment with TKIs will be included. At baseline, prior to treatment, molecular and image fingerprints are collected (fingerprint #1). Further fingerprint investigations will be performed after a short treatment period at week 4 (fingerprint #2) and optional at tumor progression (Fingerprint #3). Based on previous findings from a preceding trial the fingerprint diagnostics #1 and #2 will be used to determine a prediction for treatment outcome at the earliest possible point in time ("therapy prediction"). This prediction will be compared to the prospectively determined outcome of the treated patients in this study (validation cohort; primary study endpoint). Fingerprint #3 will be optional to generate hypothesis for treatment failure.

NCT ID: NCT01470495 Recruiting - HCC Clinical Trials

Combined Treatment of RFA and Sorafenib on Recurrent HCC

REPEAT
Start date: January 2015
Phase: N/A
Study type: Interventional

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

NCT ID: NCT01409499 Completed - Clinical trials for Hepatocellular Carcinoma

Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

2011PTAHCC
Start date: January 2011
Phase: Phase 4
Study type: Interventional

The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy or TACE. The study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.